Acadian Asset Management LLC Takes $813,000 Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Acadian Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 695,972 shares of the biopharmaceutical company's stock, valued at approximately $813,000. Acadian Asset Management LLC owned approximately 1.27% of Marinus Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in MRNS. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $34,000. Values First Advisors Inc. raised its stake in shares of Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company's stock valued at $73,000 after acquiring an additional 52,257 shares in the last quarter. Hussman Strategic Advisors Inc. grew its stake in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 10,500 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Marinus Pharmaceuticals during the 1st quarter worth about $384,000. Finally, Trexquant Investment LP purchased a new position in Marinus Pharmaceuticals in the fourth quarter worth approximately $553,000. Institutional investors and hedge funds own 98.80% of the company's stock.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock remained flat at $1.55 on Tuesday. The stock had a trading volume of 302,894 shares, compared to its average volume of 1,133,285. Marinus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $11.26. The stock has a market cap of $85.15 million, a PE ratio of -0.59 and a beta of 1.13. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The stock's fifty day moving average price is $1.35 and its 200 day moving average price is $3.00.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to analysts' expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter in the previous year, the business posted ($0.61) EPS. On average, equities research analysts predict that Marinus Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a research report on Monday. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Wednesday, August 14th. StockNews.com raised Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday, September 9th. Finally, Truist Financial reiterated a "buy" rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $10.25.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.